# Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

> **NCT05582707** · PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 1 (actual)

## Conditions studied

- Intracerebral Haemorrhage, Intraventricular

## Interventions

- **DRUG:** Pioglitazone 15mg

## Key facts

- **NCT ID:** NCT05582707
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-08
- **Primary completion:** 2024-09-19
- **Final completion:** 2025-12-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Loss of Financial Sponsor
- **Last updated:** 2026-04-28

## Collaborators

- Nico Corporation

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582707, "Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05582707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*